New Framework for Discovering Alzheimer’s Disease Biomarkers
Author Information
Author(s): Llorente-Saguer Isaac, Oxtoby Neil P
Primary Institution: University College London
Hypothesis
Can a data-driven framework improve the discovery of biomarkers for Alzheimer’s disease?
Conclusion
The BioDisCVR framework discovered superior tau PET biomarkers that significantly reduce sample size estimates for clinical trials.
Supporting Evidence
- The BioDisCVR framework reduced sample size estimates by approximately 80%.
- Results showed improved biomarker performance compared to existing methods.
- Longitudinal precision of the new biomarkers was significantly higher.
Takeaway
Researchers created a new tool to find better ways to measure Alzheimer’s disease, which could help make drug trials faster and safer.
Methodology
The study used a machine learning framework called BioDisCVR to analyze tau PET data and discover new biomarkers.
Potential Biases
Potential biases may arise from the selection of reference regions in the biomarker analysis.
Limitations
The study's findings may not generalize to all populations due to the predominance of white participants.
Participant Demographics
198 individuals from the ADNI database, with 48.7% females; 42 individuals from Mayo Clinic, with 33.3% females.
Statistical Information
P-Value
p<0.001
Confidence Interval
(195, 321)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website